Tharimmune plans Phase 2 trial for itch treatment TH104

BRIDGEWATER, NJ - Tharimmune, Inc. (NASDAQ:THAR), a biotechnology firm focused on immunology and inflammation with a current market...
20 hours ago
from: Investing.com

Clinical trial, Primary biliary cholangitis

More about this

- Tharimmune provides business update, corporate highlights
Throughout 2024 Tharimmune (THAR) achieved significant milestones across three key areas. These accomplishments reflect progress in...
from: TipRanks

- Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results
Tharimmune prepares Phase 2 study for TH104 in PBC patients following successful Phase 1 results, backed by FDA/EMA feedback and $4M funding...
from: Stock Titan